Valuation: CareDx, Inc.

Market Cap 3.36B 2.96B 2.81B 2.53B 4.77B 322B 4.84B 33.57B 12.92B 165B 12.63B 12.35B 528B P/E 2026 *
31.4x
P/E 2027 * 167x
Enterprise Value 3.36B 2.96B 2.81B 2.53B 4.77B 322B 4.84B 33.57B 12.92B 165B 12.63B 12.35B 528B EV / Sales 2026 *
6.79x
EV / Sales 2027 * 6.39x
Free-Float
96.87%
Yield 2026 *
-
Yield 2027 * -
1 day+1.53%
1 week+19.68%
1 month+29.71%
3 months+128.07%
6 months+274.42%
Current year+245.01%
1 week 60.51
Extreme 60.51
65.63
1 month 48.39
Extreme 48.3856
65.63
Current year 15.56
Extreme 15.56
65.63
1 year 13.95
Extreme 13.95
65.63
3 years 4.8
Extreme 4.8
65.63
5 years 4.8
Extreme 4.8
75.92
10 years 0.76
Extreme 0.76
99.83
Manager TitleAgeSince
Chief Executive Officer 46 2024-04-14
Director of Finance/CFO 56 2026-02-25
Chief Tech/Sci/R&D Officer - 2025-09-30
Director TitleAgeSince
Chairman 68 2021-10-31
Chairman 59 2019-12-31
Director/Board Member 70 2014-04-07
Date Insider Type Main position Quantity % Market Cap. Importance
9/12/26 Tax

Executive/Senior Manager

-6,688 0.0129%
9/12/26 Tax

Chief Financial Officer

-8,220 0.0159%
8/5/26 Sell

General Counsel

-2,688 0.0052%
Change 5-day change 1-year change 3-year change Capi.($)
+1.53%+19.68%+347.04%+828.57% 3.36B
+4.16%-0.36%+49.37%+94.17% 74.46B
-0.40%+0.96%+27.43%+80.47% 60.14B
-1.32%-0.35%+6.25%+35.08% 48.15B
-0.05%+0.37%+41.54%+36.65% 44.25B
+0.38%+7.61%+339.53%+641.55% 43.99B
+0.18%+0.26%+7.41%+103.45% 41.61B
-0.67%+0.17%+7.60%+46.37% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-1.29%-3.55%-20.74%+352.04% 24.93B
Average +0.72%+3.34%+84.22%+224.11% 40.02B
Weighted average by Cap. +0.83%+1.69%+61.64%+153.21%

Financials

2026 *2027 *
Net sales 495M 436M 413M 373M 703M 47.47B 712M 4.94B 1.9B 24.27B 1.86B 1.82B 77.81B 526M 463M 439M 396M 747M 50.43B 756M 5.25B 2.02B 25.78B 1.98B 1.93B 82.66B
Net income 116M 102M 96.64M 87.24M 164M 11.11B 167M 1.16B 445M 5.68B 435M 425M 18.2B 20.31M 17.88M 16.94M 15.3M 28.83M 1.95B 29.2M 203M 78.02M 995M 76.26M 74.6M 3.19B
Net Debt - -
Logo CareDx, Inc.
CareDx, Inc. is a precision medicine diagnostics company advancing care in transplant, specialty oncology, and cell therapy. Through non-invasive longitudinal molecular biomarker testing, digital health, and patient support solutions, the Company is focused on improving patient outcomes. The Company's integrated solutions include non-invasive molecular testing for heart, kidney, and lung transplants; digital health technologies; and patient solutions that support care before and after transplant. The Company also provides genomic-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
Employees
763
Date Price Change Volume
26-09-30 US$65.00 +1.53% 1,768,554
26-09-29 US$64.02 -0.90% 796,308
26-09-28 US$64.60 +1.44% 1,081,865
26-09-25 US$63.68 +3.76% 2,351,511
26-09-24 US$61.37 +13.00% 2,501,407
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
65.00USD
Average target price
58.83USD
Spread / Average Target
-9.49%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CDNA Stock